CRISPR Therapeutics AG (CRSP) News

CRISPR Therapeutics AG (CRSP)

Today's Latest Price: $62.26 USD

1.41 (-2.21%)

Updated Jun 5 4:00pm

Add CRSP to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 336 in Biotech

See all "A" rated Strong Buy stocks

Filter CRSP News Items

CRSP News Results

Event/TimeSymbolCompanyNews DetailStartEndChangePOWR Rating
Loading, please wait...

Latest CRSP News From Around the Web

Below are the latest news stories about CRISPR Therapeutics AG that investors may wish to consider to help them evaluate CRSP as an investment opportunity.

Better Buy: CRISPR Therapeutics vs. Intellia

The gene editing revolution is taking the market by storm, garnering the attention of large pharma companies and investors alike. This technology allows scientists to change an organism's DNA and can transform the way many diseases are treated.

Yahoo | June 3, 2020

Why Editas Medicine Is Now the CRISPR Stock to Really Watch

It's more than 2 1/2 times the size of Editas Medicine (NASDAQ: EDIT) and nearly four times larger than Intellia Therapeutics (NASDAQ: NTLA). While CRISPR Therapeutics and Intellia have captured investors' attention lately, Editas Medicine could now be the CRISPR stock to really watch. In March, Editas and its partner Allergan announced the dosing of the first patient in a phase 1/2 clinical study evaluating EDIT-101 in treating Leber congenital amaurosis type 10 (LCA10), an inherited form of blindness.

Yahoo | June 3, 2020

Here's Why Intellia Therapeutics Gained as Much as 18.0% Today

Shares of Intellia Therapeutics (NASDAQ: NTLA) rose as much as 18% today after the company announced an expansion of its partnership with Regeneron Pharmaceuticals (NASDAQ: REGN). The pair will jointly develop drug candidates to treat hereditary blood disorders hemophilia A and hemophilia B. Additionally, Regeneron Pharmaceuticals will gain rights to develop drug candidates using both in vivo (inside the body) and ex vivo (outside the body) drug candidates and delivery tools developed by Intellia Therapeutics. The gene editing pioneer will earn a combined up-front payment of $100 million in cash and equity.

Yahoo | June 1, 2020

Why Is CRISPR Therapeutics AG (CRSP) Up 22.9% Since Last Earnings Report?

CRISPR Therapeutics AG (CRSP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Investment Research | May 28, 2020

CRISPR Therapeutics to Participate in Upcoming Investor Conferences

ZUG, Switzerland and CAMBRIDGE, Mass., May 26, 2020 -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines.

Yahoo | May 26, 2020

Bull of the Day: Vertex Pharma (VRTX)

Bull of the Day: Vertex Pharma (VRTX)

Yahoo | May 19, 2020

Stocks Showing Market Leadership: CRISPR Therapeutics Earns 92 RS Rating

CRISPR Therapeutics shows rising price performance, earning an upgrade to its IBD Relative Strength Rating.

Yahoo | May 18, 2020

2 Top Gene Editing Stocks to Watch in June

Investing in gene therapy companies is no doubt an exciting venture. Indeed, sector players are rapidly making progress in combating rare or difficult to treat diseases that traditional chemical based drugs simply cannot accomplish. While the market for such novel treatments is still young, it is expected to grow by over 18% annually.

Yahoo | May 16, 2020

CRISPR Therapeutics Announces Presentations at the American Association for Cancer Research 2020 Annual Meeting

ZUG, Switzerland and CAMBRIDGE, Mass., May 15, 2020 -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines.

Yahoo | May 15, 2020

New Data for Investigational CRISPR/Cas9 Gene-Editing Therapy CTX001™ for Severe Hemoglobinopathies Accepted for Oral Presentation at the 25th European Hematology Association (EHA) Congress

ZUG, Switzerland and CAMBRIDGE, Mass. and BOSTON, May 14, 2020 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) and Vertex Pharmaceuticals…

GlobeNewswire | May 14, 2020

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.5977 seconds.